Latest Articles
Dr Lee on the Preliminary Safety of Nivolumab for Resectable dMMR Endometrial Cancer - OncLive
Dr Lee on the Preliminary Safety of Nivolumab for Resectable dMMR Endometrial Cancer OncLive
Published: April 14, 2025, 6:31 p.m.
Predicting Recurrence Risk in Endometrial Cancer: A Multisequence MRI Intratumoral and Peritumoral Radiomics Nomogram Approach - Frontiers
Predicting Recurrence Risk in Endometrial Cancer: A Multisequence MRI Intratumoral and Peritumoral Radiomics Nomogram Approach Frontiers
Published: April 10, 2025, 3:24 p.m.
Neoadjuvant Nivolumab Appears Effective for Resectable, dMMR Endometrial Cancer - Oncology Nurse Advisor
Neoadjuvant Nivolumab Appears Effective for Resectable, dMMR Endometrial Cancer Oncology Nurse Advisor
Published: April 8, 2025, 4 a.m.
Dr Lee on Responses With Nivolumab in Resectable dMMR Endometrial Cancer - OncLive
Dr Lee on Responses With Nivolumab in Resectable dMMR Endometrial Cancer OncLive
Published: March 31, 2025, 10:21 p.m.
Dr Eskander on the Potential Clinical Benefit of Nivolumab in dMMR Endometrial Cancer - OncLive
Dr Eskander on the Potential Clinical Benefit of Nivolumab in dMMR Endometrial Cancer OncLive
Published: March 27, 2025, 9:23 p.m.
Bowel Endometriosis: Systematic Approach to Diagnosis with US and MRI - RSNA Publications Online
Bowel Endometriosis: Systematic Approach to Diagnosis with US and MRI RSNA Publications Online
Published: March 20, 2025, 6:22 p.m.
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups - OncLive
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups OncLive
Published: March 17, 2025, 5:39 p.m.
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer - OncLive
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer OncLive
Published: March 16, 2025, 7:29 p.m.
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer - OncLive
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer OncLive
Published: March 15, 2025, 4:52 p.m.
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer - OncLive
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer OncLive
Published: March 15, 2025, 3:27 p.m.
Link copied to clipboard!